Efficacy and Safety of Moxidectin-Albendazole Co-administration in SAC (Moxiped)

Jennifer Keiser

Status and phase

Completed

Phase 3

Conditions

Trichuriasis

Ascariasis

Hookworm Infections

Treatments

Drug: Placebo Moxidectin

Drug: Albendazole 400 mg Oral Tablet

Drug: Moxidectin 2 mg Oral Tablet

Drug: Placebo Albendazole

Study type

Interventional

Funder types

Other

Identifiers

NCT06188715

Moxiped_1

Details and patient eligibility

About

This study is a double-blind randomized controlled superiority trial aiming at providing evidence on the efficacy and safety of co-administered moxidectin and albendazole compared to albendazole monotherapy in school-aged children (SAC; aged 6-12 years) infected with whipworm (Trichuris trichiura) on Pemba Island, Tanzania. Additionally, evidence on the safety profile of moxidectin-albendazole combination in this age group will be substantiated using a placebo (and albendazole) only arm. To date, this has only been established in adolescents (aged 16-18 years), who might present different symptoms or symptom severity compared with SAC.

As measure of efficacy of the treatment the cure rate (percentage of egg-positive subjects at baseline who become egg-negative after treatment) will be determined 14-21 days post-treatment.

Full description

The primary objective of the trial is to comparatively assess the efficacy in terms of cure rate (CR) against T. trichiura infections among SAC receiving moxidectin/albendazole combination therapy and albendazole monotherapy.

The secondary objectives of the trial are to compare the egg reduction rates (ERRs) of the treatment regimens against T. trichiura, to determine the CRs and ERRs of the drugs in study participants co-infected with A. lumbricoides and hookworm, and to evaluate the safety and tolerability of the treatment regimens.

In addition, this study aims to characterize population pharmacokinetics of moxidectin in T. trichiura infected SAC.

After obtaining informed consent from parents and/or caregivers, the medical history of the participants will be assessed with a standardized questionnaire, in addition to a clinical examination carried out by the study physician before treatment. Enrollment will be based on two stool samples, which will be collected, if possible, on two consecutive days or otherwise within a maximum of 5 days. All stool samples will be examined with duplicated Kato-Katz thick smears by experienced laboratory technicians.

Randomization of participants into the six treatment arms will be stratified according to intensity of infection and age. All participants will be interviewed before treatment, and at 3 and 24 hours and 14-21 days after treatment about the occurrence of adverse events. The efficacy of the treatment will be determined 14-21 days post-treatment by collecting another two stool samples.

The primary analysis will include all participants with primary end point data (available case analysis). Supplementary, a per-protocol analysis will be conducted. CRs will be calculated as the percentage of egg-positive participants at baseline who become egg-negative after treatment. Differences among CRs between treatment arms will be analysed using crude and adjusted logistic regression modeling (adjustment for age, sex and weight). Geometric and arithmetic mean egg counts will be calculated for the different treatment arms before and after treatment to assess the corresponding ERRs. Bootstrap resampling method with 5,000 replicates will be used to calculate 95% confidence intervals (CIs) for differences in ERRs. Adverse events will be compiled into frequency tables and compared between treatment groups using descriptive summary statistics.

Enrollment

224 patients

Sex

All

Ages

6 to 12 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

individuals aged 6-12 years (confirmed by birth certificate or similar document)
having given written informed consent signed by parents/caregivers
being able and willing to provide two stool samples at baseline and at follow-up assessment (14-21 days)
having at least two out of four Kato-Katz slides positive for T. trichiura at baseline
being able and willing to be examined by a study physician before and after treatment

Exclusion criteria

presence or signs of major systemic illness, e.g. fever (temporal body temperature of >38.0°C), severe anaemia (haemoglobin level of <80 g/l)
history of severe acute disease or unmanaged, severe chronic disease (i.e., condition is not as therapeutically controlled as necessary)
use of anthelminthic drugs during study period
known allergy to study medication (i.e., moxidectin or albendazole)
being prescribed or taking concomitantly medication with known contraindications or drug interactions with the study medication
pregnancy (female participants aged 10-12 years)
concurrent participation in other clinical trials

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

224 participants in 3 patient groups, including a placebo group

Arm A: Moxidectin 4/8 mg & Albendazole

Experimental group

Description:

Combination therapy of moxidectin (4 mg or 8 mg, i.e. 2 or 4 tablets of 2 mg) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0

Treatment:

Drug: Moxidectin 2 mg Oral Tablet

Drug: Albendazole 400 mg Oral Tablet

Arm B: Albendazole

Active Comparator group

Description:

Placebo for moxidectin (2 or 4 tablets) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0

Treatment:

Drug: Albendazole 400 mg Oral Tablet

Drug: Placebo Moxidectin

Arm C: Placebo

Placebo Comparator group